Semaglutide's Cardiovascular Promise
The advent of generic semaglutide in India presents a significant opportunity for patient health, particularly concerning cardiovascular event reduction.
Groundbreaking research, notably the SELECT trial published in The New England Journal of Medicine and spearheaded by A. Michael Lincoff, has illuminated the drug's potential. This extensive study, involving 17,604 participants over approximately 40 months, demonstrated that a weekly dose of semaglutide could decrease major cardiovascular events by 20%. Crucially, this benefit was observed in adults who had pre-existing cardiovascular disease but did not have diabetes, provided their body mass index (BMI) was 27 or higher. This finding marks a pivotal moment in understanding how semaglutide can serve individuals beyond those with diabetes, offering a new avenue for managing cardiac risks in specific patient profiles.
BMI Thresholds: A Potential Barrier
While the SELECT trial offers promising results, a critical concern is emerging regarding the applicability of its findings in the Indian context. Aditi Kantipuly, a resident in preventive medicine and public health at McGill University and a visiting scholar at the University of New Mexico, has voiced significant apprehension. She highlights that the established BMI threshold of 27, used in global trials, might inadvertently exclude a substantial portion of high-risk patients in India. The demographic and physiological characteristics of the Indian population often differ from those in Western countries, meaning that individuals who are at considerable risk for cardiovascular issues might fall below this standard BMI cutoff. Consequently, many Indians who could potentially benefit from semaglutide's protective effects might be denied access if these global thresholds are rigidly applied, underscoring a pressing need for localized clinical considerations and revised guidelines to ensure equitable healthcare.
